ASX - By Stock
|
CNJ |
Re:
Ann: Placement and Pro-Rata Non-Renounceable Rights Offer
|
|
Viper_00
|
60 |
19K |
0 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
60
|
19K
|
0
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Placement and Pro-Rata Non-Renounceable Rights Offer
|
|
Viper_00
|
60 |
19K |
1 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
60
|
19K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Appendix 4C Cash Flow Report
|
|
Viper_00
|
7 |
3.9K |
2 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
7
|
3.9K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira receives $919,000 R&D Tax Incentive Scheme Refund
|
|
Viper_00
|
2 |
905 |
1 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
2
|
905
|
1
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Becoming a substantial holder
|
|
Viper_00
|
27 |
7.8K |
1 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
27
|
7.8K
|
1
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Placement and Pro-Rata Non-Renounceable Rights Offer
|
|
Viper_00
|
60 |
19K |
4 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
60
|
19K
|
4
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Placement and Pro-Rata Non-Renounceable Rights Offer
|
|
Viper_00
|
60 |
19K |
0 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
60
|
19K
|
0
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Suspension from Quotation
|
|
Viper_00
|
42 |
12K |
0 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
42
|
12K
|
0
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Suspension from Quotation
|
|
Viper_00
|
42 |
12K |
8 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
42
|
12K
|
8
|
|
ASX - By Stock
|
ZLD |
Re:
Summary
|
|
Viper_00
|
39 |
19K |
4 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
39
|
19K
|
4
|
|
ASX - By Stock
|
CNJ |
Re:
Technical analysis
|
|
Viper_00
|
2 |
936 |
2 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
2
|
936
|
2
|
|
ASX - By Stock
|
IHL |
Re:
Missing shares 17/10/2023
|
|
Viper_00
|
359 |
99K |
0 |
25/01/24 |
25/01/24 |
ASX - By Stock
|
359
|
99K
|
0
|
|
ASX - By Stock
|
IHL |
Re:
Ann: Shareholder Support and Instructions
|
|
Viper_00
|
975 |
280K |
1 |
12/01/24 |
12/01/24 |
ASX - By Stock
|
975
|
280K
|
1
|
|
ASX - By Stock
|
IHL |
Re:
Trading on NASDAQ
|
|
Viper_00
|
307 |
115K |
1 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
307
|
115K
|
1
|
|
ASX - By Stock
|
IHL |
Re:
Trading on NASDAQ
|
|
Viper_00
|
307 |
115K |
0 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
307
|
115K
|
0
|
|
ASX - By Stock
|
IHL |
Re:
General discussion
|
|
Viper_00
|
19K |
6.5M |
0 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
19K
|
6.5M
|
0
|
|
ASX - By Stock
|
IHL |
Re:
General discussion
|
|
Viper_00
|
19K |
6.5M |
0 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
19K
|
6.5M
|
0
|
|
ASX - By Stock
|
IHL |
Re:
General discussion
|
|
Viper_00
|
19K |
6.5M |
0 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
19K
|
6.5M
|
0
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
Viper_00
|
30 |
13K |
1 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
30
|
13K
|
1
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
Viper_00
|
55 |
25K |
2 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
55
|
25K
|
2
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
Viper_00
|
55 |
25K |
1 |
28/08/23 |
28/08/23 |
ASX - By Stock
|
55
|
25K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Viper_00
|
217 |
71K |
5 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
217
|
71K
|
5
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Viper_00
|
217 |
71K |
4 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
217
|
71K
|
4
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: GSR:Mt Thirsty Mineral Resource Increases By Over 145%
|
|
Viper_00
|
17 |
11K |
9 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
17
|
11K
|
9
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Trading Halt
|
|
Viper_00
|
27 |
14K |
1 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
27
|
14K
|
1
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Trading Halt
|
|
Viper_00
|
27 |
14K |
2 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
27
|
14K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Viper_00
|
13 |
4.3K |
0 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
13
|
4.3K
|
0
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Placement and Pro-Rata Nonrenounceable Rights Issue
|
|
Viper_00
|
31 |
18K |
0 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
31
|
18K
|
0
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Placement and Pro-Rata Nonrenounceable Rights Issue
|
|
Viper_00
|
31 |
18K |
2 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
31
|
18K
|
2
|
|
ASX - By Stock
|
CNJ |
Re:
Ann: Placement and Pro-Rata Nonrenounceable Rights Issue
|
|
Viper_00
|
31 |
18K |
1 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
31
|
18K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira Retail Investor Briefing Details
|
|
Viper_00
|
10 |
3.7K |
4 |
11/11/22 |
11/11/22 |
ASX - By Stock
|
10
|
3.7K
|
4
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira Retail Investor Briefing Details
|
|
Viper_00
|
10 |
3.7K |
0 |
07/11/22 |
07/11/22 |
ASX - By Stock
|
10
|
3.7K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Investor group update meet the CEO hmmm
|
|
Viper_00
|
3 |
1.0K |
0 |
07/11/22 |
07/11/22 |
ASX - By Stock
|
3
|
1.0K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
CBD & Cannabidiol now available over the counter
|
|
Viper_00
|
19 |
6.8K |
4 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
19
|
6.8K
|
4
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Response to ASX Aware Query
|
|
Viper_00
|
26 |
8.4K |
4 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
26
|
8.4K
|
4
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zenivol receives formal BfArM approval in Germany
|
|
Viper_00
|
23 |
11K |
3 |
18/07/22 |
18/07/22 |
ASX - By Stock
|
23
|
11K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Hope 1 Longitudinal, Real-World Data Trial in ASD Results
|
|
Viper_00
|
99 |
39K |
2 |
11/07/22 |
11/07/22 |
ASX - By Stock
|
99
|
39K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Hope 1 Longitudinal, Real-World Data Trial in ASD Results
|
|
Viper_00
|
99 |
39K |
1 |
11/07/22 |
11/07/22 |
ASX - By Stock
|
99
|
39K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Hope 1 Longitudinal, Real-World Data Trial in ASD Results
|
|
Viper_00
|
99 |
39K |
0 |
11/07/22 |
11/07/22 |
ASX - By Stock
|
99
|
39K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Hope 1 Longitudinal, Real-World Data Trial in ASD Results
|
|
Viper_00
|
99 |
39K |
0 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
99
|
39K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Hope 1 Longitudinal, Real-World Data Trial in ASD Results
|
|
Viper_00
|
99 |
39K |
0 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
99
|
39K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Hope 1 Longitudinal, Real-World Data Trial in ASD Results
|
|
Viper_00
|
99 |
39K |
1 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
99
|
39K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Pause in Trading
|
|
Viper_00
|
12 |
5.6K |
0 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
12
|
5.6K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: EDCDM Technology License Agreement Update
|
|
Viper_00
|
29 |
9.2K |
3 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
29
|
9.2K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: EDCDM Technology License Agreement Update
|
|
Viper_00
|
29 |
9.2K |
1 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
29
|
9.2K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: EDCDM Technology License Agreement Update
|
|
Viper_00
|
29 |
9.2K |
4 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
29
|
9.2K
|
4
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
|
|
Viper_00
|
7 |
3.5K |
2 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
7
|
3.5K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
General discussion
|
|
Viper_00
|
395 |
159K |
5 |
26/04/22 |
26/04/22 |
ASX - By Stock
|
395
|
159K
|
5
|
|
ASX - By Stock
|
ZLD |
Re:
General discussion
|
|
Viper_00
|
395 |
159K |
3 |
26/04/22 |
26/04/22 |
ASX - By Stock
|
395
|
159K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
General discussion
|
|
Viper_00
|
395 |
159K |
3 |
26/04/22 |
26/04/22 |
ASX - By Stock
|
395
|
159K
|
3
|
|